Radiation therapy before liver transplant or surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if a targeted radiation treatment, called SIRT, can shrink liver tumors enough to allow for a liver transplant or surgical removal. It is for people with liver cancer who are not yet eligible for these procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a diagnosis of liver cancer that can be seen on a CT or MRI scan.
- You cannot have received prior cancer treatment (like chemotherapy or immunotherapy) for your liver cancer, but you may have had certain local treatments in the past, such as surgery, ablation, or TACE.
- Your cancer must be within specific size and number limits depending on whether the goal is to bridge to transplant (smaller tumors) or downstage (somewhat larger tumors).
- Your liver function must be fairly good, as measured by the Child-Pugh score (A5, A6, or B7).
- You cannot have cancer that has spread outside the liver or into the main portal vein.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted internal radiation treatment for people with liver cancer (HCC) that is too widespread for surgery and goes beyond the up-to-7 criteria. It aims to see if this therapy can safely and effectively treat tumors that are all located in a specific area of the liver.
This trial tests combining an immunotherapy drug (sintilimab) with focused radiation (SBRT) before surgery for liver cancer that has spread into a branch of the portal vein. The goal is to see if this combination can shrink the tumor and make surgery more successful.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests a targeted radiation treatment (SIRT) for people with liver cancer that is still confined to one side of the liver and has not been treated before. The goal is to see if SIRT can shrink the tumor enough to make surgical removal possible.
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.